Lixte Biotechnology Holdings Inc. (LIXTW)
LIXTE Biotechnology Announces $16,566,027 Registered Direct Offering Priced at the Market Under Nasdaq Rules, Strengthening Balance Sheet for Next Phase of Strategic Growth
LIXTE Biotechnology Announces $16,566,027 Registered Direct Offering Priced at the Market Under Nasdaq Rules, Strengthening Balance Sheet for Next Phase of Strategic Growth
Maravai LifeSciences Announces Refinancing of Credit Agreement, Extending Maturity to 2032
Maravai LifeSciences Announces Refinancing of Credit Agreement, Extending Maturity to 2032
LIXTE Biotechnology Announces $16,566,027 Registered Direct Offering Priced at the Market Under Nasdaq Rules, Strengthening Balance Sheet for Next Phase of Strategic Growth
Tempus Launches Open-Source Digital Pathology Consortium, Names Yale New Haven Health and Leading Cancer Center as Founding Members
SharkNinja Launches the Shark Home Luxe Collection, Bringing a New Design Standard to the Cleaning Category
Sapu Nano Expands International Development of Sapu003 and Appoints Global Clinical Trials (GCT) as Lead CRO for Phase 1b Program
OSI Systems Receives $10 Million Award for Optical Sub-Assemblies
Charles River Associates (CRA) to Present at the Sidoti Small-Cap Virtual Conference
Hongli Group Inc. Updates Its Business Strategy, Focusing on Solid-State Lithium Batteries